Vera Therapeutics Inc
NASDAQ:VERA
Vera Therapeutics Inc
NASDAQ:VERA
Price:
45.04
USD
10.04%
Market Closed
Market Cap:
$3.2B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Vera Therapeutics Inc
NASDAQ:VERA
|
US |
|
China Water Affairs Group Ltd
HKEX:855
|
HK |
|
X
|
Xcelplus International Inc
OTC:XLPI
|
US |
|
Atom Hoteles Socimi SA
MAD:YATO
|
ES |
|
F
|
Fairfax Financial Holdings Ltd
TSX:FFH.U
|
CA |
|
Otso Gold Corp
XTSX:OTSO
|
CA |
|
Duos Technologies Group Inc
NASDAQ:DUOT
|
US |
|
C
|
CGS International Inc
OTC:CGSI
|
US |
|
EQUUS Total Return Inc
NYSE:EQS
|
US |
|
Hunter Group ASA
OSE:HUNT
|
NO |
|
S
|
Spectrum Pharmaceuticals Inc
F:NTR
|
US |
|
Komax Holding AG
SIX:KOMN
|
CH |
|
Freshii Inc
TSX:FRII
|
CA |
|
Urbi Desarrollos Urbanos SAB de CV
BMV:URBI
|
MX |
|
I
|
Indofood CBP Sukses Makmur Tbk PT
OTC:PIFFY
|
ID |
Multiples-Based Value
The
Multiples-Based Value for
Vera Therapeutics Inc (VERA)
under the Base Case is
hidden
USD.
Compared with the current market price of 45.04 USD, the stock appears
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
VERA Multiples-Based Value
LOCKED
Multiples Across Competitors
VERA Competitors Multiples
Vera Therapeutics Inc Competitors
Vera Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Vera Therapeutics Inc
NASDAQ:VERA
|
3.2B USD | 0 | -10.7 | -8.2 | -8.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
367.6B USD | 6 | 87.8 | 14.6 | 20.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
189.2B USD | 5.1 | 24.5 | 14.2 | 14.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
172.5B USD | 5.9 | 20.3 | 12.7 | 15.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.8B USD | 9.2 | 28 | 21 | 22 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.2B USD | 5.5 | 17.6 | 13 | 14.8 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.2B EUR | 11.9 | 38.2 | 41.3 | 42.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.1B AUD | 3 | 32.9 | 11.1 | 13.9 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
